title: Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life.
abstract: BACKGROUND
  Depression is now seen as a chronic disabling condition that spans the patient's lifetime and creates significant medical, economic and quality of life consequences.
  
  
  METHODS
  500 depressed patients were treated with milnacipran for 6 months. A total of 214 recovered patients were randomised to receive either milnacipran (50 mg bid) or a matching placebo for a 1-year recurrence prevention phase. Recurrence rate was the primary criteria; quality of life (QoL) consequences were evaluated through a shortened version of the French Sickness Impact Profile (SIP), the Depression Impact Profile (DIP).
  
  
  RESULTS
  Milnacipran demonstrated its ability to reduce recurrences (Odds-Ratio=1.5; P<0.05), with a more marked effect in recovered patients with few residual symptoms (Odds-Ratio=3.0). Responders who continued treatment with milnacipran had a dramatic improvement in their quality of life, although patients with residual symptoms still experienced some deterioration in their QoL (recreation, emotional, social, alertness and home assistance scores). Even recovered patients having zero scores on the Hamilton Depression Rating Scale-21 items (HDRS) had some QoL deterioration. The DIP emotional score was found to be more predictive of recurrence than the HDRS. Overall, the QoL was improved for those in the milnacipran group in comparison to placebo on the mobility, communication, psycho-social and total scores.
  
  
  CONCLUSIONS
  The QoL evaluation was a secondary criteria; no a priori sample size estimate was performed. The choice of a generic QoL instrument might have reduced the sensitivity to clinical changes in depression.
  
  
  CONCLUSIONS
  Prevention of recurrence in MDD with milnacipran contributes to an improvement in the QoL.
authors.affiliation: Hôpital Louis Mourier, 178, Rue des Renouillers, F-92701, Colombes, France.
authors.forename: F
authors.initials: F
authors.lastname: Rouillon
authors.forename: G
authors.initials: G
authors.lastname: Berdeaux
authors.forename: J C
authors.initials: JC
authors.lastname: Bisserbe
authors.forename: B
authors.initials: B
authors.lastname: Warner
authors.forename: M
authors.initials: M
authors.lastname: Mesbah
authors.forename: C
authors.initials: C
authors.lastname: Smadja
authors.forename: J
authors.initials: J
authors.lastname: Chwalow
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003521:Cyclopropanes / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078764:Milnacipran; D011788:Quality of Life; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D003521:Cyclopropanes; D000078764:Milnacipran